About US
Contact us
-
What spurred Lilly, Novo and Sanofi to slash insulin prices? Expert gives her takeNot one, not two, but three of the industry's top diabetes players last month slashed prices on their competing insulins. After Eli Lilly's cut, the strategy was quickly followed by Novo Nordisk and2023/4/17
-
With hard-fought Polivy approval, Roche looks to shake up decades of established practice in lymphomaAfter a regulatory scare, Roche can now kick off work on changing nearly 20 years of clinical practice for the treatment of diffuse large B-cell lymphoma (DLBCL). The FDA has signed off o2023/4/14
-
Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats upA series of acquisitions by GSK, Merck & Co. and Sanofi has analysts at RBC Capital Markets optimistic about the biopharma M&A landscape. And the team has some potential targets in mind.2023/4/14
-
Pfizer moves on up to the West Side, establishing new nerve center at Hudson Yards' Spiral skyscraperFrom medication to meditation, Pfizer’s new West Side Manhattan headquarters is a ritzy real-estate ode to its workers. For more than sixty years, Pfizer has operated out of a revamped re2023/4/12
-
Phathom says it has Voquezna back on track after nitrosamine-related delayA meeting with the FDA has paved the way for Phathom Pharmaceuticals to resubmit its applications for its erosive esophagitis and Helicobacter pylori drug Voquezna, the companysaidon Tuesday.2023/4/12
-
Novartis' Sandoz must cough up $39M after losing patent fight with Allergan and Duke UniversityLess than a week after Allergan and Duke University dropped their allegation that Novartis' Sandoz willfully infringed Duke’s patent for eyelash growth serum Latisse (bimatoprost), a federal jury in2023/4/10
-
Ahead of Pfizer buyout, Seagen's Padcev gains Keytruda combo nod in first-line bladder cancerWhile Merck & Co.’s Seagen merger wasn't fated to be, the companies’ clinical courtship in cancer has blossomed into a swift approval at the FDA. Monday, the U.S. drug regulatorblesse2023/4/10
-
Amid dispute with FDA, Akebia proposes new dosing for oral anemia drug in kidney diseaseAkebia Therapeutics isn’t giving up on its oral anemia drug vadadustat despite an FDA rejection and a partnership gone awry. Now, just as the company challenges the FDA decision, Akebia has offered t2023/4/6
-
Viatris maintains legal winning streak with yet another EpiPen antitrust victoryAs another round of EpiPen marketing litigation wraps, Mylan’s successor Viatris can chalk up another victory. Late last week, a federal court in New Yorktossedinvestors’ claims against V2023/4/6
-
Apellis Pharma and its rare disease, eyecare drugs draw takeover interest: BloombergAmid a recent streak of rare disease M&A deals in the biopharma industry, Apellis has attracted takeover interest, Bloomberg reports. The rare diseases and ophthalmology specialist is2023/4/4